PL2868315T3 - Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty - Google Patents

Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty

Info

Publication number
PL2868315T3
PL2868315T3 PL14188334T PL14188334T PL2868315T3 PL 2868315 T3 PL2868315 T3 PL 2868315T3 PL 14188334 T PL14188334 T PL 14188334T PL 14188334 T PL14188334 T PL 14188334T PL 2868315 T3 PL2868315 T3 PL 2868315T3
Authority
PL
Poland
Prior art keywords
lyophilates
lyophilization
methods
improved formulations
formulations
Prior art date
Application number
PL14188334T
Other languages
English (en)
Polish (pl)
Inventor
Martin Sven Jacobson
Original Assignee
Biogen Chesapeake Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Chesapeake Llc filed Critical Biogen Chesapeake Llc
Publication of PL2868315T3 publication Critical patent/PL2868315T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL14188334T 2007-12-04 2008-12-03 Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty PL2868315T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99224107P 2007-12-04 2007-12-04
EP08857974.3A EP2224913B1 (en) 2007-12-04 2008-12-03 Improved formulations and methods for lyophilization and lyophilates provided thereby
EP14188334.8A EP2868315B1 (en) 2007-12-04 2008-12-03 Improved formulations and methods for lyophilization and lyophilates provided thereby

Publications (1)

Publication Number Publication Date
PL2868315T3 true PL2868315T3 (pl) 2018-06-29

Family

ID=40718143

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14188334T PL2868315T3 (pl) 2007-12-04 2008-12-03 Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty

Country Status (14)

Country Link
US (6) US8277845B2 (enExample)
EP (2) EP2224913B1 (enExample)
JP (5) JP5812318B2 (enExample)
CN (1) CN101932308B (enExample)
CA (3) CA3123813C (enExample)
CY (1) CY1119256T1 (enExample)
DK (1) DK2868315T3 (enExample)
ES (1) ES2638977T3 (enExample)
HR (1) HRP20171223T1 (enExample)
LT (1) LT2868315T (enExample)
PL (1) PL2868315T3 (enExample)
PT (1) PT2868315T (enExample)
SI (1) SI2868315T1 (enExample)
WO (1) WO2009073711A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8277845B2 (en) 2007-12-04 2012-10-02 Remedy Pharmaceuticals, Inc. Formulations and methods for lyophilization and lyophilates provided thereby
US20110034560A1 (en) 2008-01-29 2011-02-10 Sven Jacobson Liquid formulations of compounds active at sulfonylurea receptors
WO2013086292A1 (en) * 2011-12-09 2013-06-13 Enject, Inc. Glucagon formulations
WO2013169939A2 (en) 2012-05-08 2013-11-14 Aeromics, Llc New methods
FI3597749T3 (fi) * 2012-05-25 2023-10-09 Univ California Menetelmiä ja koostumuksia rna-ohjattua kohde-dna-modifikaatiota varten ja rna-ohjattua transkription modulaatiota varten
US9155695B2 (en) 2013-03-14 2015-10-13 Medtronic, Inc. Injectable ropinirole compositions and methods for making and using same
KR20160079109A (ko) 2013-11-06 2016-07-05 에어로믹스, 인코포레이티드 새로운 조성물
JP6645979B2 (ja) * 2014-03-07 2020-02-14 エンドーロジックス インコーポレイテッド ヒドロゲルを形成する改善された方法およびその材料
TW201613888A (en) 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
WO2016196113A1 (en) 2015-05-29 2016-12-08 University Of Maryland, Baltimore Methods of reducing or preventing intimal damage caused by mechanical stimulation of endothelial cells
BR112018006925A2 (pt) 2015-10-07 2018-10-16 Biogen Chesapeake Llc métodos de tratamento de lesões ou patologias associadas com um edema do snc
US20170320862A1 (en) 2016-05-03 2017-11-09 Cadila Healthcare Limited Process for the preparation of brexpiprazole and intermediates thereof
CA3032294C (en) 2016-07-29 2025-03-11 Biogen Chesapeake Llc MEDICAL TREATMENT METHODS WITH SUR1-TRPM4 CHANNEL INHIBITORS
CN108210501B (zh) * 2016-12-14 2019-03-08 中国人民解放军军事医学科学院毒物药物研究所 一种磺酰脲类药物的注射用药物组合物及其制备方法
EP3647229B1 (en) 2017-06-30 2022-09-07 Murata Machinery, Ltd. Conveying system and conveying method
CN108553428A (zh) * 2018-05-29 2018-09-21 昆药集团股份有限公司 格列本脲制剂及其制备方法
CA3210407A1 (en) * 2021-03-04 2022-09-09 Kenny K. Tran Low-sorbing glyburide formulation and methods
CA3213821A1 (en) 2021-03-19 2022-09-22 Eligo Bioscience Therapeutic use of engineered postbiotics comprising bacteriocins and/or endolysins
CN113274361B (zh) * 2021-06-08 2022-05-06 吉林津升制药有限公司 一种烟酰胺冻干粉针剂及其制备方法
JP2025506895A (ja) * 2022-03-03 2025-03-13 レメディー ファーマシューティカルズ， インコーポレイテッド 低吸着性グリブリドキット、製剤および方法
US12251388B1 (en) 2024-05-09 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
US12251389B1 (en) 2024-04-22 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4384975A (en) 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
DE3833439A1 (de) 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
GB9003185D0 (en) * 1990-02-13 1990-04-11 Ici Plc Pharmaceutical compositions
ATE146359T1 (de) 1992-01-21 1997-01-15 Stanford Res Inst Int Verbessertes verfahren zur herstellung von mikronisierter polypeptidarzneimitteln
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
EP0757688A1 (en) * 1994-04-25 1997-02-12 Kyowa Hakko Kogyo Co., Ltd. Method for stabilizing compound dx-52-1 and lyophilized composition thereof
US5747002A (en) 1995-04-05 1998-05-05 Genentech, Inc. Preparation of sodium chloride aerosol formulations
US5856360A (en) * 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
US5817343A (en) 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
TR199901968T2 (xx) * 1996-12-24 1999-12-21 Biogen, Inc. Sabit s�v� interferon form�lleri.
US5859037A (en) 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
PT999826E (pt) 1997-07-29 2004-09-30 Upjohn Co Formulacao auto-emulsionante para compostos lipofilos
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
JP2002516874A (ja) * 1998-05-29 2002-06-11 バイオジェン インコーポレイテッド 組換えヒトインターフェロンβ−１Ａ（ＩＦＮ−β−１Ａ）処方物
JP3956654B2 (ja) 2000-06-29 2007-08-08 小野薬品工業株式会社 Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物含有溶液および製剤
US6552082B2 (en) 2000-06-29 2003-04-22 Ono Pharmaceutical Co., Ltd. Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
AU2002306461A1 (en) 2001-03-28 2002-10-15 Rheologics, Inc. In vivo delivery methods and compositions
US20080220441A1 (en) * 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
JP2005501817A (ja) * 2001-06-12 2005-01-20 アクティブ パス ファーマシューティカルズ， インコーポレイテッド β−アミロイド産生を調節する化合物、組成物および方法
WO2003007951A1 (en) * 2001-07-17 2003-01-30 N-Gene Research Laboratories Inc. A synergistic pharmaceutical combination for the prevention or treatment of diabetes
US7872048B2 (en) * 2004-09-18 2011-01-18 University Of Maryland, Baltimore Methods for treating spinal cord injury with a compound that inhibits a NCCa-ATP channel
PT2438913T (pt) * 2002-03-20 2020-05-27 Us Veterans Affairs Canal de catiões não seletivos em células neurais e compostos que bloqueiam o canal para utilização no tratamento de edema cerebral
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
DE10325989A1 (de) 2003-06-07 2005-01-05 Glatt Gmbh Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
GB0316237D0 (en) * 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
DE10341414A1 (de) 2003-09-05 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Oral zu applizierende Darreichungsform für schwerlösliche saure und amphotere Wirkstoffe
JP5000493B2 (ja) * 2004-05-20 2012-08-15 ディアメディカ インコーポレイテッド インスリン抵抗性を治療するための製薬組成物、同製薬組成物の調製においてベタネコール及びｎ−アセチルシステインを使用する方法及び同製薬組成物を含むキット
AU2006215703A1 (en) * 2005-02-17 2006-08-24 Instituto Del Metabolismo Celular, S.L. L-aspartic acid for the treatment of problems in connection with the fat or glucose metabolism
US7659281B2 (en) * 2006-04-25 2010-02-09 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors
CA2663610C (en) 2006-09-29 2015-11-03 Infa S.A. Packaging system for pharmaceutical compositions and kit for intravenous administration
US8277845B2 (en) * 2007-12-04 2012-10-02 Remedy Pharmaceuticals, Inc. Formulations and methods for lyophilization and lyophilates provided thereby

Also Published As

Publication number Publication date
WO2009073711A1 (en) 2009-06-11
EP2224913B1 (en) 2014-10-15
EP2224913A1 (en) 2010-09-08
PT2868315T (pt) 2017-09-04
JP2020007334A (ja) 2020-01-16
US8277845B2 (en) 2012-10-02
CA2707484A1 (en) 2009-06-11
JP2011505424A (ja) 2011-02-24
EP2868315B1 (en) 2017-05-31
US20100273886A1 (en) 2010-10-28
US8858997B2 (en) 2014-10-14
JP2015134763A (ja) 2015-07-27
ES2638977T3 (es) 2017-10-24
JP6084639B2 (ja) 2017-02-22
CN101932308B (zh) 2014-11-05
JP2017128569A (ja) 2017-07-27
US10426729B2 (en) 2019-10-01
CY1119256T1 (el) 2018-02-14
LT2868315T (lt) 2017-09-25
SI2868315T1 (sl) 2017-10-30
EP2868315A1 (en) 2015-05-06
HRP20171223T1 (hr) 2017-11-03
JP2018197244A (ja) 2018-12-13
JP6377189B2 (ja) 2018-08-22
US10117834B2 (en) 2018-11-06
CA3240562A1 (en) 2009-06-11
JP5812318B2 (ja) 2015-11-11
CA3123813A1 (en) 2009-06-11
CN101932308A (zh) 2010-12-29
US20210244669A1 (en) 2021-08-12
US10869835B2 (en) 2020-12-22
US20200093747A1 (en) 2020-03-26
US20190099372A1 (en) 2019-04-04
DK2868315T3 (en) 2017-09-04
JP6866438B2 (ja) 2021-04-28
US20130245069A1 (en) 2013-09-19
CA2707484C (en) 2021-08-10
JP6603762B2 (ja) 2019-11-06
EP2224913A4 (en) 2013-04-24
CA3123813C (en) 2024-10-08
US20150141516A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
HRP20171223T1 (hr) Poboljšane formulacije i postupci liofiliziranja i tako dobiveni liofilizati
EP2043647A4 (en) FORMULATION WITH TAXED RELEASE AND CORRESPONDING METHODS
ZA201203709B (en) Immunogenic compositions and methods
ZA200905621B (en) Solid preparation comprising alogliptin and pioglitazone
SG10201501296SA (en) Lyophilized therapeutic peptibody formulations
IL197781A0 (en) Lyophilization methods and apparatuses
ZA200808489B (en) Nicotine-carrier vaccine formulation
EP2111215A4 (en) MATERIALS AND METHOD FOR THE ADMINISTRATION OF ANTIOXIDANTS IN THE SKIN
EP2367444A4 (en) MEDICAL AND NUTRITIONAL FORMULATIONS
IL211670A0 (en) Therapeutic protein formulations
EP2209750A4 (en) CEMENT FORMULATIONS AND PRODUCTS
EP2160183A4 (en) QUETIPIN EXTENDED FORMULATIONS WITH EXTENDED RELEASE AND METHOD OF MANUFACTURING THEREOF
GB0719202D0 (en) Compositions and methods for the skin and hair
SMT202000110T1 (it) Composizioni farmaceutiche e metodi per la loro stabilizzazione
ZA200903049B (en) Polymer-linked-bisphosphonate inhalant formulations and methods for using the same
PL2207567T3 (pl) Preparat immunogenny
EP2300018A4 (en) PAEONIFLORINE PREPARATIONS AND THEIR USE OF FAT REDUCTION
GB0719248D0 (en) Compounds and methods for pharmaceutical use
ZA201003524B (en) Injectable meclizine formulations and methods
EP2348865A4 (en) BETA-HYDROXY-GAMMA-AMINOPHOSPHONATES, THEIR METHODS OF PREPARATION AND THEIR USE
ZA201008384B (en) Lasalocid compositions and methods
GB0711465D0 (en) Silan-3-amines and disilan-5-amines as therapeutic agents
GB0725007D0 (en) Carcino-immune therapeutic animal gland extract
GB0713093D0 (en) Pharmaceutical formulations
GB0715066D0 (en) Tobacco extraction methods and formulations